Notably, in malignant PCs, the sustained expression of c-Myc and IRF4 is a consequence of activating mutations and translocations, and their levels increase during MM progression from early stage MGUS to symptomatic MM, suggesting a major role for these transcription factors in the pathogenesis of the disease [31,32]. The gene discussed is MYC; the disease is Miyoshi myopathy.